New Fabry Drug Report Drags Amicus Down

Boston, MA 02/19/2013 (wallstreetpr) – Amicus Therapeutics, Inc. (NASDAQ:FOLD) had been working on a drug called migalastat. This drug was being developed for the treatment of a rare genetic disorder named Fabry disease which is caused when body cells buildup a certain type of fat. This fat is highly detrimental to the health in that it does irrevocable damage to the nervous system as well as the kidneys.

The company stocks have been devalued by 50% since Dec 19th, 2012. Amicus and GlaxoSmithKline plc (ADR) (NYSE:GSK), its partner had made a joint announcement then that the drug had failed to meet its main goal. This report had already made a negative impact on the performance of its stocks and in its wake came the most current announcement.

The latest negative secondary goal results reported by Amicus Therapeutics Inc (NASDAQ:FOLD) post certain clinical trials, brought its shares tumbling down by $1 to $2.89. This was a drop of 25.7 percent.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares were down by 25.71% to $2.89.

GlaxoSmithKline plc (ADR) (NYSE:GSK) shares were down by 0.09% to $45.62.

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Donna Fago

I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.